{"id":942785,"date":"2026-03-08T17:03:06","date_gmt":"2026-03-08T21:03:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/"},"modified":"2026-03-08T17:03:06","modified_gmt":"2026-03-08T21:03:06","slug":"dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/","title":{"rendered":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK and WALTHAM, Mass., March  08, 2026  (GLOBE NEWSWIRE) &#8212; Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow, Monday, March 9, 2026 at 8:00 a.m. ET.<\/p>\n<p>\n        <strong>Investor Conference Call &amp; Webcast Information<\/strong><br \/>\n        <br \/>To access the live conference call by phone, please register\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6c2V9Y4DIcNQa2vRxbxaBHri201F11uMbDujtlS7V0i2Ypf9Y_ODb896hz1gs9_qkVG3VUSeAWf-KN0zPfvJWpmUd_U11UvBCfQ5WcAVJAVysyv8dvsQ3khLWVamcz1dMjKvZkVMVzeWLJPE9-CkR3bL0nhDCjgMftLshyqWMJk=\" rel=\"nofollow\" target=\"_blank\">here<\/a>.\u00a0Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN.\u00a0<\/p>\n<p>The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ot1U1wyHukWPwtjDwxt5Qisd2Nb7KZp9nSwiSR1CG8_0t6UKLpuwbyzvUEDhmnPO7bshcxZh2Ol4rw5o5U3Us7sWS6CZUCSrG_CKCGDWFUQVoormQ3VnVoovBV0FgUpZ\" rel=\"nofollow\" target=\"_blank\">live webcast<\/a> may be accessed via the Investors section of the Dianthus Therapeutics website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zWRlEbt58WF4bFR2auoi1x6-DoqxEFs19OuJ4yxvOyC18Yyh0ft4S_hEuv4T_uGcR3tQyCg2nTz9V2wdUks9Dh_YRDVigL8L5Nb7CgDFMwjbF106usEVZ5PxfPAc1krr\" rel=\"nofollow\" target=\"_blank\">https:\/\/investor.dianthustx.com\/<\/a>. A replay of the webcast will be available following the call.<\/p>\n<p>\n        <strong>About Dianthus Therapeutics<\/strong><br \/>\n        <br \/>Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.<\/p>\n<p>To learn more, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PDbtoyGR_cOSYIEMJH_SyVGEvf3oYk0HO1nW2eBV2MvXDL6JO_ifZS8JG7r29LsVddJCZP4CCfX9xRxvaJRD1ok061qqIV5b5UzFUM0rhuY=\" rel=\"nofollow\" target=\"_blank\"><u>www.dianthustx.com<\/u><\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KQM9NJoTkv-NzfreyUf9nRNCJOVQfjPn_n6Zmpx-3QphNhk0ritjcTKfTVBed-DxH7FxqVpHk282FIWiQb4G8svjQZSxHvApKIyspmLS93lr9Xho0prLTEz7Ye7NPi7SuavGyXn8-q3GmKYsfSRuQw==\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>.\u00a0<\/p>\n<p>\n        <strong>Contact <\/strong><br \/>\n        <br \/>Jennifer Davis Ruff<br \/>Dianthus Therapeutics<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HMCgFSK_aQqUh0d9fvdvNd2h82PtntOAZeRI3kjECcxQYcWi6dcCGPZ02FgEmfgiOEAbsp_zntETGKJBQoVZhhyfoV9m7TAov1ACdvkPTt5UyT8fuaX0IsPcmYRlDW4_\" rel=\"nofollow\" target=\"_blank\">jdavisruff@dianthustx.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NzkyMiM3NDczNjIxIzIyNjAzODk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2FjNTFiZWYtNzBmMy00MTJiLThiYmUtZWUzNGNkNjRjYWYzLTEyNzE5MzktMjAyNi0wMy0wOC1lbg==\/tiny\/Dianthus-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) &#8212; Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow, Monday, March 9, 2026 at 8:00 a.m. ET. Investor Conference Call &amp; Webcast Information To access the live conference call by phone, please register\u00a0here.\u00a0Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN.\u00a0 The live webcast may be accessed via the Investors section of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-942785","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) &#8212; Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow, Monday, March 9, 2026 at 8:00 a.m. ET. Investor Conference Call &amp; Webcast Information To access the live conference call by phone, please register\u00a0here.\u00a0Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN.\u00a0 The live webcast may be accessed via the Investors section of &hellip; Continue reading &quot;Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-08T21:03:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NzkyMiM3NDczNjIxIzIyNjAzODk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)\",\"datePublished\":\"2026-03-08T21:03:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\\\/\"},\"wordCount\":245,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NzkyMiM3NDczNjIxIzIyNjAzODk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\\\/\",\"name\":\"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NzkyMiM3NDczNjIxIzIyNjAzODk=\",\"datePublished\":\"2026-03-08T21:03:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NzkyMiM3NDczNjIxIzIyNjAzODk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY2NzkyMiM3NDczNjIxIzIyNjAzODk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/","og_locale":"en_US","og_type":"article","og_title":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Newsdesk","og_description":"NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) &#8212; Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow, Monday, March 9, 2026 at 8:00 a.m. ET. Investor Conference Call &amp; Webcast Information To access the live conference call by phone, please register\u00a0here.\u00a0Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN.\u00a0 The live webcast may be accessed via the Investors section of &hellip; Continue reading \"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-08T21:03:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NzkyMiM3NDczNjIxIzIyNjAzODk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","datePublished":"2026-03-08T21:03:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/"},"wordCount":245,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NzkyMiM3NDczNjIxIzIyNjAzODk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/","name":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NzkyMiM3NDczNjIxIzIyNjAzODk=","datePublished":"2026-03-08T21:03:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NzkyMiM3NDczNjIxIzIyNjAzODk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY2NzkyMiM3NDczNjIxIzIyNjAzODk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/dianthus-therapeutics-to-host-conference-call-and-webcast-to-discuss-the-interim-responder-analysis-results-of-the-phase-3-captivate-trial-of-claseprubart-in-chronic-inflammatory-demyelinating-polyneu\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=942785"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/942785\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=942785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=942785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=942785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}